Evotec Biologics赢得人工智能驱动的单克隆抗体优化拨款

2026-01-08 15:01

Evotec SE (EVO) (EVOTF) Thursday reported that its Seattle-based subsidiary, Just-Evotec Biologics, has received a new grant from the Gates Foundation to enable global access to biotherapeutics utilizing Just-Evotec Biologics' molecular design suite of computational technologies, called "J.MD^™".
Just - Evotec Biologics will optimize monoclonal antibodies ("mAbs") and other biologic modalities.
This grant extends the commitment of Just - Evotec Biologics, which began in 2014 and has since delivered multiple cGMP manufacturing campaigns for RSV, malaria, and HIV monoclonal antibodies, the company said.

More on Evotec SE